ABSTRACT-Since 1990, red sea bream 11-dov virus (RSIV) has to this virus (authors' unpubl, data). Diseased fish caused high mortalities in the summertime in cultured red sea became lethargic and exhibited severe anemid,
petechiae of the gills, and enlargement of the spleen lneasures for red sea bream iridoviral disease (RSIVD), the effectiveness of a formalin-killed viral vaccine was evaluated (' "' ' ye et ). In addition, the pathogenicity of Red sea bream iridovirus (RSIV) causes an acute and highly contagious disease, tentatively designated red sea bream iridoviral disease (RSIVD). Since 1990, outbreaks of RSIVD have resulted in high mortalities in cultured red sea bream Pagrus major in southwest Japan, primarily in the summertime. The disease has caused mass mortalities among cultured marine fish, which include 18 Perciformes, 1 Pleuronectiformes and 1 Tetradontiformes (Matsuoka et al. 1996) . A recent survey showed that 25 species of fish are susceptible EHNV, SFIV and GIV to red sea bream has not been demonstrated . Diagnostic methods such as an IF test and polymerase chain reaction amplification were reported , Kurita et al. 1998 , Oshima et al. 1998 ). However, control measures for this disease have not been established. Recently, we reported on the effectiveness of a vaccine against RSIVD under laboratory conditions (Nakajima et al. 1997) . Herein, w e describe the results regarding the effectiveness of the vaccine evaluated in a field trial.
Materials and methods. To evaluate the vaccine, 2000 red sea bream juveniles (mean body weight 6.2 g ) were divided into 2 groups (vaccinated group and nonvaccinated group). For the vaccinated group, fish were intraperitoneally inoculated with 0.1 m1 of vaccine solution made from the supernatant of RSIV-infected
Grunt fin (GF) cells. For the preparation of a vaccine
Results and discussion. At 12 d post vaccination, morfrom the supernatant of RSIV-infected GF cells, the talities were first observed in the control groups. Beculture medium of RSIV-infected GF cells was centween 40 and 50 d post vaccination, mortalities peaked tnfuged at 2500 X g for 10 min at 4°C. Formalin (0.1 % (Fig. 1B) and the cumulative mortalities caused by RSIV V/V) was then added to the supernatant, which conin control non-treated fish were 68.5 % (Fig. 1A) . Howtained 107.5 TCIDSO ml-' of the virus, and the virus was ever, deaths among vaccinated fish began later than inactivated for 12 d at 4°C; then inactivation of the those among control fish, and the cumulative mortality virus was confirmed. The other group, which served as in vaccinated fish caused by RSIV was 19.2% (Fig. 1) . controls, were non-treated. After vaccination, the vacThe dead fish exhibited severe anemia, petechiae of cinated fish were kept in tanks for 1 wk then moved to the gill, and enlargement of spleen, which are typical a seawater net pen (2.5 X 2.5 X 2.5 m). The control fish signs of the disease. Viral antigens were detected from were kept in tanks for 1 wk and moved to a seawater the spleens of dead fish. The results showed that the net pen neighboring the net pen which contained the vaccinated groups had a higher relative survival than vaccinated fish. Mortality in these groups was recorded the control group. RPS of the vaccinated fish was 72%. daily for 12 wk post vaccination, and the diagnosis of x2 analysis showed differences in the mortalities of the RSIVD was made on the basis of clinical signs of disease and by means of an IF test with a MAb previously described . Fixed imprints of the spleen -were covered with MAb M10 and allowed to incubate at 37OC for 30 min in a humidified chamber. After the slides had been rinsed 3 times for 1 min with phosphate-buffered saline (PBS), the secondary antibody with fluorescein isothiocyanate (F1TC)-conjugated goat anti-mouse IgG was applied at 37°C for 30 min. The preparates were rinsed again with PBS, mounted in glycerol, and examined with a microscope to identify IF-positive cells. For the diagnosis of RSIVD, all the dead fish were examined on the basis of clinical signs of disease. For the diagnosis of RSIVD using an IF test with a MAb, all fish were examined when the number of fish which had died was less than 10 fish at 1 sampling. When 5 the number of fish which had died 50 exceeded 10 at 1 sampling, 10 fish were 4 examined. Sampling was done once a day. Statistical analysis was carried out using a x2 test. The relative percentage survival (RPS, Amend, 1981) was also determined by the formula RPS = [ l -(% loss of immunized fish/% loss of l.
controls)] X 100. To detect viral antigen, 10 survivors were randomly sampled in each group. Then, the spleens were vaccinated and non-vaccinated groups to be significant (p < 0.01). This disease frequently occurs when the ambient temperature is more than 25°C. Thus, the decline in temperature was responsible for the decline in morbidity (Fig. 1B) .
The presence of viral antigen in the spleen was also examined. In the vaccinated group, viral antigen was not detected in 10 fish examined at 6 or 12 wk post vaccination. In contrast, in the control group, viral antigen was detected in all the 10 fish examined at 6 wk, but was not detected in the 10 fish examined at 12 wk post vaccination. These results showed that the vaccine prevented the appearance of viral antigen in the spleen of immunized fish at 6 wk post vaccination, when mortalities caused by RSIV frequently occurred. The average body weights of vaccinated and control fish were 35.6 5.12 and 30.8 + 5.12 g at 6 wk post vaccination and 66.4 +. 9.14 and 63.6 + 10.3 g at 12 wk post vaccination, respectively. The difference in the increase in the body weight of fish in the vaccinated and non-vaccinated group is statistically significant (p < 0.05).
In addition to the effectiveness of the vaccine in an experimental infection previously reported (Nakajinla et al. 1997) , this vaccine against RSIVD has proven successful in the prevention of RSIVD in red sea bream in 1 field trial. Therefore, this vaccine will be the control measure for this disease. The development of a killed virus vaccine and of an injection delivery method will be a very important health management tool in the prevention of RSIVD. This disease has occurred not only in red sea bream but also in various other cultured marine fish. The causative viruses isolated from various diseased fish were shown to be similar . So, the effectiveness of the vaccine in cultured marine fish is also promising. In addition to the trial reported here involving red seabream, further trials using cultured marine fish such as yellowtail Seriola quinqueradiata, amberjack Senola dumerili, striped jack Pseudocaranx dentex are needed. 
